CCB
PVLA

Cutter & Co Brokerage’s Palvella Therapeutics PVLA Stock Holding History

Cutter & Co Brokerage’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,718
Closed -$370K – 222
2023
Q1 		$370K Sell
4,718
-13
-0.3% -$1.5K 0.12% 124
2022
Q4 		$394K Sell
4,731
-351
-7% -$28.2K 0.13% 117
2022
Q3 		$468K Sell
5,082
-71
-1% -$9.15K 0.17% 104
2022
Q2 		$771K Buy
5,153
+75
+1% +$13.7K 0.26% 79
2022
Q1 		$1.23M Buy
5,078
+143
+3% +$37.6K 0.37% 63
2021
Q4 		$1.49M Buy
4,935
+859
+21% +$275K 0.41% 58
2021
Q3 		$1.69M Buy
+4,076
New +$1.42M 0.4% 72

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cutter & Co Brokerage's PVLA Position: Q2 2023 in Review

Cutter & Co Brokerage sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 4,718 shares — an estimated $370K sold.

Cutter & Co Brokerage first reported a position in PVLA in Q3 2021 and held it in 7 quarters. The position peaked at $1.69M in Q3 2021. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • Cutter & Co Brokerage reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cutter & Co Brokerage sold 4,718 Palvella Therapeutics shares in Q2 2023, an estimated $370K.
  • Cutter & Co Brokerage first reported a position in Palvella Therapeutics in Q3 2021 and held it in 7 quarters.
  • Cutter & Co Brokerage's Palvella Therapeutics position peaked at $1.69M in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Cutter & Co Brokerage's 13F filing for Q2 2023, filed 1 Aug 2023.